Home › NDC Lookup › RxCUI directory › RxCUI 1147337

Emtricitabine 200 MG / rilpivirine 25 MG / tenofovir disoproxil fumarate 300 MG Oral Table... — RxCUI 1147337

RxNorm drug concept · Semantic branded drug
RxCUI 1147337 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1147337
Official nameEmtricitabine 200 MG / rilpivirine 25 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Complera]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asCOMPLERA 200 MG / 25 MG / 300 MG Oral Tablet; Complera (emtricitabine 200 MG / rilpivirine 25 MG (as rilpivirine hydrochloride 27.5 MG) / tenofovir disoproxil fumarate 300 MG (as tenofovir disoproxil 245 MG)) Oral Tablet
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)2,706 prescriptions · 21 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Emtricitabine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Emtricitabine doesn't cure HIV, but it's an important part of keeping the virus under control. It works by blocking an enzyme HIV needs to make copies of itself. When it's used alo...
  • What exactly does emtricitabine do — does it cure HIV?
  • Please don't stop without talking to your doctor first. If you also have hepatitis B, stopping emtricitabine can trigger a sudden, severe flare of hepatitis B — sometimes serious e...
  • Can I stop taking emtricitabine if I feel fine or if I also have hepatitis B?
📖 Read our full Emtricitabine guide →

🕸️ Concept Web — How Emtricitabine 200 MG / rilpivirine 25 MG / tenof... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Emtricitabine 200 MG / rilpivirine 25 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Complera] RxCUI 1147337

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Emtricitabine 276237
    • Rilpivirine 1102270
    • Tenofovir disoproxil 300195
    • Emtricitabine / rilpivirine / tenofovir disoproxil 1145801
    • Tenofovir disoproxil fumarate 322248
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Complera 1145803
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Emtricitabine / rilpivirine / tenofovir disoproxil Oral Tablet 1145800
    • Emtricitabine / rilpivirine / tenofovir disoproxil fumarate Oral Tablet 2647691
    • Emtricitabine / rilpivirine / tenofovir disoproxil Oral Product 1161303
    • Emtricitabine / rilpivirine / tenofovir disoproxil Pill 1161304
    • Emtricitabine / rilpivirine / tenofovir disoproxil fumarate Oral Product 2661902
    • Emtricitabine / rilpivirine / tenofovir disoproxil fumarate Pill 2662188
    • Emtricitabine / rilpivirine / tenofovir disoproxil Oral Tablet [Complera] 1145805
    • Emtricitabine / rilpivirine / tenofovir disoproxil fumarate Oral Tablet [Complera] 2655774
    • +5 more in this family
  4. Clinical & branded drugs 5

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 19 of 24 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Emtricitabine 200 MG / rilpivirine 25 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet SCD · 1147334
  • Emtricitabine 200 MG SCDC · 406016
  • Rilpivirine 25 MG SCDC · 1102271
  • Tenofovir disoproxil fumarate 300 MG SCDC · 393334
  • Emtricitabine / rilpivirine / tenofovir disoproxil Oral Tablet SCDF · 1145800
  • Emtricitabine / rilpivirine / tenofovir disoproxil fumarate Oral Tablet SCDFP · 2647691
  • Emtricitabine / rilpivirine / tenofovir disoproxil Oral Product SCDG · 1161303
  • Emtricitabine / rilpivirine / tenofovir disoproxil Pill SCDG · 1161304
  • Emtricitabine / rilpivirine / tenofovir disoproxil fumarate Oral Product SCDGP · 2661902
  • Emtricitabine / rilpivirine / tenofovir disoproxil fumarate Pill SCDGP · 2662188

Brand-Name Concepts

  • Emtricitabine 200 MG / rilpivirine 25 MG / tenofovir disoproxil fumarate 300 MG [Complera] SBDC · 1147336
  • Emtricitabine / rilpivirine / tenofovir disoproxil Oral Tablet [Complera] SBDF · 1145805
  • Emtricitabine / rilpivirine / tenofovir disoproxil fumarate Oral Tablet [Complera] SBDFP · 2655774
  • Complera Oral Product SBDG · 1167416
  • Complera Pill SBDG · 1167417
  • Complera BN · 1145803

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1147337 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
61958-1101-01 30 TABLET, FILM COATED in 1 BOTTLE (61958-1101-1) COMPLERA Gilead Sciences, Inc. 2011-08-10
Observed labelers: Gilead Sciences, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$130.1410
Range $130.1410–$130.1410 · middle 50% $130.1410–$130.1410 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.